Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Fulcrum Therapeutics, Inc. (FULC) had Income from Continuous Operations of $-20.33M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-20.33M |
|
-- |
|
-- |
|
$22.69M |
|
$-22.69M |
|
$2.36M |
|
$-20.33M |
|
$-20.33M |
|
$-20.33M |
|
|
Income from Continuous Operations |
$-20.33M |
$-20.33M |
|
$-20.33M |
|
$-22.69M |
|
$-22.35M |
|
63.35M |
|
63.35M |
|
$-0.31 |
|
$-0.31 |
|
| Balance Sheet Financials | |
$357.48M |
|
$2.82M |
|
$8.80M |
|
$366.28M |
|
$13.05M |
|
-- |
|
$4.24M |
|
$17.28M |
|
$349.00M |
|
$349.00M |
|
$349.00M |
|
66.58M |
|
| Cash Flow Statement Financials | |
$-60.06M |
|
$30.72M |
|
$168.67M |
|
$59.41M |
|
$198.73M |
|
$139.32M |
|
$12.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-60.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.83% |
|
-5.83% |
|
-5.55% |
|
-5.83% |
|
$5.24 |
|
$-0.95 |
|
$-0.95 |
|